 |
To print: Click here or Select File and then Print from your browser's menu
BMS & AstraZeneca begin phase-4 trial of Saxgliptin in type-2 diabetes with cardio risk factors
Thursday, March 11, 2010 13:00 IST
Princeton, New Jersey
Bristol-Myers Squibb Company and AstraZeneca announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53)
Read complete story ...
(You will need to login first to read this story.)
|
